MEDIVIR AB – INTERIM REPORT JANUARY – MARCH 2023

“Thanks to the strong interest from clinicians and patients, we were able to swiftly dose the first patients in the phase 2a part of the combination study with fostrox and Lenvima® in HCC after completed dose escalation”January – MarchFinancial summary for the quarter · Net turnover amounted to SEK 0.4 (0.5) million. · The loss before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -18.9(-31.4) million. Basic and diluted earnings per share amounted to SEK -0.34 (-0.59) and SEK -0.34 (-0.59) respectively. · Cash flow from operating activities amounted